Acrivon Therapeutics OverviewAcrivon Therapeutics EBIT
EBIT (Earnings Before Interest and Taxes) analysis for ACRV.
Quarterly EBIT
-$19.90M
↑ 8.12% YoY
As of Mar 31, 2026
Annual EBIT (TTM)
-$87.43M
↑ 6.18% YoY
Trailing 12 months ending Mar 31, 2026
Acrivon Therapeutics OverviewEBIT (Earnings Before Interest and Taxes) analysis for ACRV.
As of Mar 31, 2026
Trailing 12 months ending Mar 31, 2026